Efficacy of Mindfulness-based Pain Management in Patients With Chronic Pain With and Without Fibromyalgia
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 112
- 试验地点
- 2
- 主要终点
- Change in Lattinen Index- IL
研究概览
简要总结
Today, one of the most important challenges of the health system is the attitude towards chronic disorders. That implies changing from a health structure established for the treatment of acute diseases to a continued care system.
In this sense, the approach of chronic pain, of non-oncological origin, supposes an important care challenge, to which this project wishes to respond.
Chronic pain affects one of every Europeans (19%), and has a prevalence of 11% in Spain, being one of the most important causes of medical consultation and is associated with high personal, social and economic costs. For example, in 2017 it was calculated that it has an economic impact of between 1.7 and 2.1% of Spain's GDP.
Referred to the psychological consequences of the disease, it has been found that 42% of people who have chronic pain suffer insomnia, a 40% anxiety, and 24% depressive symptoms. Hence the importance of implementing evidence-based psychological treatments along with their treatment as usual The main objective is comparing the efficacy of mindfulness-based pain management (MBPM), together with the usual medical treatment, in patients diagnosed with chronic pain, with and without comorbid fibromyalgia.
Specific objectives are:
- To study the sociodemographic and clinical profile of patients with chronic pain, with and without fibromyalgia.
- Define the characteristics of patients who are in the different stages of the disease: stage 1 (less than two years since diagnosis); stage 2 (between 2 and 4 years); stage 3 (between 5 and 8 years), and stage 4 (more than 8 years).
- Check the effectiveness of psychological therapies MBPM depending on the presence of fibromyalgia.
- Check the effectiveness of the psychological treatment in function of the stage of the disease.
Method:
A quasi-experimental design of two groups will be used. Patients will be assigned to experimental group: 50 subjects will receive MBPM and control group 40 subjects, 3-months wait list, after which time they will also receive MBPM.
All the participants will be assessed in the baseline; at the end of the treatment; and in the 1, 3, 6 and 12 months follow-ups. Group 2 (waiting list) will be assessed in the baseline, and re-assessed before starting the treatment; at the end of the psychological therapy; and in the 1, 3, 6 and 12 months follow-ups.
详细描述
The objetive of this research are the study of efficacy in chronic pain and fybromyalgia of mindfulness therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Be able to complete the assessment protocol
- •Suffer from chronic non-oncological pain, lasting longer than 6 months
- •Not being receiving psychological treatment
- •Sign the informed consent
排除标准
- •Present a cognitive impairment, such as a dementia
- •Present a diagnosis of a psychotic disease, bipolar disease or additive disease
结局指标
主要结局
Change in Lattinen Index- IL
时间窗: base line (week 0), end of treatment (week 12); and during maintenance phase (weeks 17, 29 and 41)
It is a scale with five items to assess variables associated with pain: frequency, intensity, disability, drugs usage and sleep problems. These are assessed by a Likert scale of 0 to 4, in order to explain the discomfort that pain generates. (Gonzalez-Escada, 2012)
次要结局
- Change in the Fibromyalgia Impact Questionnaire- FIQ(base line (week 0), end of treatment (week 12); and during maintenance phase (weeks 17, 29 and 41))
- Change in the Listado de Sintomas Breve- LSB-50(base line (week 0), end of treatment (week 12); and during maintenance phase (weeks 17, 29 and 41))
- Change in the Short Form 12 Health Survey- SF-12(base line (week 0), end of treatment (week 12); and during maintenance phase (weeks 17, 29 and 41))
- Change in Cuestionario de afrontamiento del dolor- CAD-R(base line (week 0), end of treatment (week 12); and during maintenance phase (weeks 17, 29 and 41))
- Change in Connor-Davison Resilience Scale- CDRISC(base line (week 0), end of treatment (week 12); and during maintenance phase (weeks 17, 29 and 41))
- Change in Inventaire of negative thoughts in response to pain- INTRP(base line (week 0), end of treatment (week 12); and during maintenance phase (weeks 17, 29 and 41))
- Change Pain Catastrophizing Scale- PCS(base line (week 0), end of treatment (week 12); and during maintenance phase (weeks 17, 29 and 41))
- Change in Chronic Pain Acceptance Questionnaire- CPAQ(base line (week 0), end of treatment (week 12); and during maintenance phase (weeks 17, 29 and 41))
研究者
Karmele Salaberria
PhD. Lecturer in Psychology
University of the Basque Country (UPV/EHU)